News

Public · Published

HeartBeam Announces Positive Heart Attack Pilot Study Results at TCT 2026: Patient-Recorded 3D ECG Shown to Be as Accurate as Standard 12-Lead ECG

HeartBeam said its ALIGN-ACS pilot study produced positive results evaluating the company's patient-recorded 3D ECG system for heart attack assessment. Results were presented by Graham Nichol of the University of Washington at the TCT 2026 conference. The headline says the 3D ECG was as accurate as a standard 12-lead ECG.

Published:

Updated:

What happened

HeartBeam said its ALIGN-ACS pilot study produced positive results evaluating the company’s patient-recorded 3D ECG system for heart attack assessment. Results were presented by Graham Nichol of the University of Washington at the TCT 2026 conference. The headline says the 3D ECG was as accurate as a standard 12-lead ECG.

Confirmed

Global impact / market context

If the study’s result holds in broader testing, a patient-recorded ECG could help physicians assess suspected heart attacks remotely and direct patients to emergency care sooner. That may support demand for HeartBeam’s device, but the supplied text gives no study details, sales, or commercial timetable.

Analyst inference

HeartBeam says its device is portable, cable-free, and designed for on-demand patient recordings, while capturing three-dimensional heart signals. The company describes a potential US coronary artery disease market of 20 million people, but the article provides no evidence of adoption, reimbursement, or revenue.

Confirmed

What to watch

  1. Look for further study details, including participant numbers and how accuracy was measured, because the article reports positive pilot results but gives no methods or numerical findings. Analyst inference
  2. Watch for larger clinical studies or regulatory updates; the article says the technology has FDA Breakthrough Device Designation, a program designation that does not itself establish commercial approval. Confirmed
  3. Track whether physicians and patients adopt remote ECG assessment, since actual use would determine whether the device can shorten care delays and generate meaningful sales. Analyst inference

Evidence

  • Original source link unavailable